The diagnosis and treatment of myotonic disorders

Muscle and Nerve

Volumn 47, Issue 5, 2013, Pages 632-648

  Heatwole, Chad R ^a   Statland, Jeffrey M ^a   Logigian, Eric L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Myotonia; Myotonic dystrophy; Nondystrophic myotonia; Therapeutics

Indexed keywords

ACETAZOLAMIDE; AMINO ACID; AMITRIPTYLINE; CARBAMAZEPINE; CLOMIPRAMINE; DANTROLENE; FLECAINIDE; IMIPRAMINE; MEXILETINE; NIFEDIPINE; PHENYTOIN; PLACEBO; PRASTERONE SULFATE; PROCAINAMIDE; QUININE; TAURINE; TOCAINIDE;

AGRANULOCYTOSIS; ANOREXIA; BECKER MUSCULAR DYSTROPHY; CENTRONUCLEAR MYOPATHY; DIPLOPIA; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; EXERCISE TEST; FATIGUE; GASTROINTESTINAL SYMPTOM; GENETIC SCREENING; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERPIGMENTATION; HYPOKALEMIC PERIODIC PARALYSIS; HYPOTENSION; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG FIBROSIS; MALIGNANT HYPERTHERMIA; MENTAL DISEASE; MUSCLE CONTRACTION; MUSCLE CRAMP; MUSCLE TRAINING; MYOTONIA; MYOTONIC DYSTROPHY; NEPHROLITHIASIS; NONHUMAN; OSTEOPOROSIS; PARESTHESIA; POLYMYOSITIS; PRIORITY JOURNAL; QUADRIPLEGIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TIME; REVIEW; SCHWARTZ JAMPEL SYNDROME; SEDATION; SIDE EFFECT; SKELETAL MUSCLE; SPASTICITY; STIFF MAN SYNDROME; TACHYCARDIA; TASTE DISORDER; THOMSEN DISEASE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

CHLORIDE CHANNELS; HUMANS; MUSCLE, SKELETAL; MYOTONIA; MYOTONIC DISORDERS; SODIUM CHANNELS;

EID: 84876805809     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23683     Document Type: Review

References (156)

1. Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118:547-563.
2. Alon M, Korczyn AD. Pupillary responses and blink reflex in myotonic dystrophy. Clin Auton Res 1992;2:17-19.
3. Harvey JC, Sherbourne DH, Siegel CI. Smooth muscle involvement in myotonic dystrophy. Am J Med 1965;39:81-90.
4. Preston D, Shapiro B. Electromyography and neuromuscular disorders. Boston: Butterworth-Heinemann; 1998.541-559 p.
5. Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve 1987;10:603-615.
6. Kimura J. Electrodiagnosis in diseases of nerve and muscle. Philadelphia: F.A. Davis; 1989. p 252-254.
7. Trip J, Drost G, van Engelen BGM, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev 2006;2.
8. Logigian EL, Blood CL, Dilek N, Martens WB, Moxley RT, Wiegner AW, et al. Quantitative analysis of the "warm-up" phenomenon in myotonic dystrophy type 1. Muscle Nerve 2005;32:35-42.
9. Moxley RT III, Logigian EL, Martens WB, Annis CL, Pandya S, Moxley RT, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve 2007;36:320-328.
10. Logigian EL, Twydell P, Dilek N, Martens WB, Quinn C, Wiegner AW, et al. Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1. Muscle Nerve 2010;41:191-196.
11. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat 2002;19:423-434.
12. Brown GL, Harvey AM. Congenital myotonia in the goat. Brain 1939;62:341-341-363.
13. Ryan AM, Matthews E, Hanna MG. Skeletal-muscle channelopathies: periodic paralysis and nondystrophic myotonias. Curr Opin Neurol 2007;20:558-563.
14. Burge JA, Hanna MG. Novel insights into the pathomechanisms of skeletal muscle channelopathies. Curr Neurol Neurosci Rep 2012;12:62-69.
15. Hodgkin AL, Horowicz P. The influence of potassium and chloride ions on the membrane potential of single muscle fibres. J Physiol 1959;148:127-160.
16. Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibres and the action of monocarboxylic aromatic acids. J Physiol 1971;219:367-383.
17. Adrian RH, Bryant SH. On the repetitive discharge in myotonic muscle fibres. J Physiol 1974;240:505-515.
18. Koch MC, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992;257:797-800.
19. George AL Jr, Crackower MA, Abdalla JA, Hudson AJ, Ebers GC. Molecular basis of Thomsen's disease (autosomal dominant myotonia congenita). Nat Genet 1993;3:305-310.
20. Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R. X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 2002;415:287-294.
21. Duffield M, Rychkov G, Bretag A, Roberts M. Involvement of helices at the dimer interface in ClC-1 common gating. J Gen Physiol 2003;121:149-161.
22. Mitrovic N, George AL Jr, Lerche H, Wagner S, Fahlke C, Lehmann-Horn F. Different effects on gating of three myotonia-causing mutations in the inactivation gate of the human muscle sodium channel. J Physiol 1995;487:107-114.
23. Hayward LJ, Brown RH Jr, Cannon SC. Inactivation defects caused by myotonia-associated mutations in the sodium channel III-IV linker. J Gen Physiol 1996;107:559-576.
24. Cummins TR, Zhou J, Sigworth FJ, Ukomadu C, Stephan M, Ptacek LJ, et al. Functional consequences of a Na+ channel mutation causing hyperkalemic periodic paralysis. Neuron 1993;10:667-678.
25. Yang N, Ji S, Zhou M, Ptacek LJ, Barchi RL, Horn R, et al. Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc Natl Acad Sci USA 1994;91:12785-12789.
26. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci 2006;29:387-415.
27. Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10:35-44.
28. Wheeler TM, Sobczak K, Lueck JD, Osborne RJ, Lin X, Dirksen RT, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009;325:336-339.
29. Trip J, Drost G, Ginjaar HB, Nieman FH, van der Kooi AJ, de Visser M, et al. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. J Neurol Neurosurg Psychiatry 2009;80:647-652.
30. Moxley RT. Approach to the evaluation of myotonia. American Academy of Neurology Lecture; 2004.
31. Heatwole CR, Moxley RT. The non-dystrophic myotonias. NeuroRX 2007;4:238-251.
32. Rudel R, Dengler R, Ricker K, Haass A, Emser W. Improved therapy of myotonia with the lidocaine derivative tocainide. J Neurol 1980;222:275-278.
33. Matthews E, Manzur AY, Sud R, Muntoni F, Hanna MG. Stridor as a neonatal presentation of skeletal muscle sodium channelopathy. Arch Neurol 2011;68:127-129.
34. Milone M, McEvoy KM, Sorenson EJ, Daube JR. Myotonia associated with caveolin-3 mutation. Muscle Nerve 2012;45:897-900.
35. Dumitru D, Amato A. Introduction to myopathies and muscle tissue's reaction to injury. In: Electrodiagnostic medicine. Philadelphia: Hanley and Belfus; 2002.1229-1264 p.
36. Amato A, Dumitru D. Hereditary myopathies. In: Electrodiagnostic medicine. Philadelphia: Hanley and Belfus; 2002.1265-1370 p.
37. Moxley RT, Tawil R. Channelopathies,: myotonic disorders and periodic paralysis. In: Swaiman KAshwal S, Ferriero D, editors.Pediatric neurology,: principles and practice. Philadelphia. Mosby: Mosby; 2006.
38. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-1258.
39. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, Jansen G, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 1992;255:1253-1255.
40. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992;69:385.
41. Harper P. Myotonic dystrophy. Philadelphia: Saunders; 2001.
42. Gadalla SM, Lund M, Pfeiffer RM, Gortz S, Mueller CM, Moxley RT III, et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011;306:2480-2486.
43. Logigian EL, Ciafaloni E, Quinn LC, Dilek N, Pandya S, Moxley RT III, et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007;35:479-485.
44. New nomenclature and DNA testing guidelines for myotonic dystrophy type, 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology 2000;54:1218-1221.
45. Griggs RC, Wood DS. Criteria for establishing the validity of genetic recombination in myotonic dystrophy. Neurology 1989;39:420-421.
46. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003;73:835-848.
47. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-867.
48. Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998;19:196-198.
49. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007;20:572-576.
50. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-664.
51. Moxley RT III, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002;12:306-317.
52. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Speich N, Reiners K, et al. Proximal myotonic myopathy. Clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995;52:25-31.
53. Thornton CA, Griggs RC, Moxley RT III. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994;35:269-272.
54. Heatwole C, Moxley R. Channelopathies: myotonic disorders and periodic paralysis. In: Swaiman's pediatric principles and practice 5th ed. Philadelphia: Elsevier Saunders; 2012.
55. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003;60:657-664.
56. Meola G, Moxley RT III. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004;251:1173-1182.
57. Davies NP, Hanna MG. Neurological channelopathies: diagnosis and therapy in the new millennium. Ann Med 1999;31:406-420.
58. Shapiro B, Ruff R. Disorders of skeletal muscle membrane excitability myotonia congenita, paramyotonia congenita, periodic paralysis, and related disorders. In: Katirji B, Kaminski H, Preston D, Ruff R, Shapiro B, editors. Neuromuscular disorders in clinical practice. Boston: Butterworth-Heinemann; 2002.987-1020p.
59. Becker P, Knussmann R, Kuhn E. Myotonia congenita and syndromes assoicated with myotonia. In: Topics in human genetics. Vol. III. Stuttgart: Thieme; 1977.1-178 p.
60. Gutmann L, Phillips LH II. Myotonia congenita. Semin Neurol 1991;11:244-248.
61. Duno M, Colding-Jorgensen E, Grunnet M, Jespersen T, Vissing J, Schwartz M. Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype. Eur J Hum Genet 2004;12:738-743.
62. Koty PP, Pegoraro E, Hobson G, Marks HG, Turel A, Flagler D, et al. Myotonia and the muscle chloride channel: dominant mutations show variable penetrance and founder effect. Neurology 1996;47:963-968.
63. Russell SH, Hirsch NP. Anaesthesia and myotonia. Br J Anaesth 1994;72:210-216.
64. Colding-Jorgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve 2005;32:19-34.
65. Fournier E, Viala K, Gervais H, Sternberg D, Arzel-Hezode M, Laforet P, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol 2006;60:356-365.
66. Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004;56:650-661.
67. Wagner S, Deymeer F, Kurz LL, Benz S, Schleithoff L, Lehmann-Horn F, et al. The dominant chloride channel mutant G200R causing fluctuating myotonia: clinical findings, electrophysiology, and channel pathology. Muscle Nerve 1998;21:1122-1128.
68. Lehmann-Horn F, Mailander V, Heine R, George AL. Myotonia levior is a chloride channel disorder. Hum Mol Genet 1995;4:1397-1402.
69. Zwarts MJ, van Weerden TW. Transient paresis in myotonic syndromes. A surface EMG study. Brain 1989;112:665-680.
70. Drost G, Blok JH, Stegeman DF, van Dijk JP, van Engelen BG, Zwarts MJ. Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: a high-density surface EMG study. Brain 2001;124:352-360.
71. Ptacek LJ, Trimmer JS, Agnew WS, Roberts JW, Petajan JH, Leppert M. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. Am J Hum Genet 1991;49:851-854.
72. Ptacek LJ, Gouw L, Kwiecinski H, McManis P, Mendell JR, Barohn RJ, et al. Sodium channel mutations in paramyotonia congenita and hyperkalemic periodic paralysis. Ann Neurol 1993;33:300-307.
73. McClatchey AI, Trofatter J, McKenna-Yasek D, Raskind W, Bird T, Pericak-Vance M, et al. Dinucleotide repeat polymorphisms at the SCN4A locus suggest allelic heterogeneity of hyperkalemic periodic paralysis and paramyotonia congenita. Am J Hum Genet 1992;50:896-901.
74. Streib EW. Paramyotonia congenita. Semin Neurol 1991;11:249-257.
75. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 2010;133:9-22.
76. Brooke M. Disorders of skeletal muscle. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. Boston: Butterworth-Heinemann; 2000.2187-2235 p.
77. Moxley RT III. Channelopathies. Curr Treat Options Neurol 2000;2:31-47.
78. Ricker K, Lehmann-Horn F, Moxley RT III. Myotonia fluctuans. Arch Neurol 1990;47:268-272.
79. Ricker K, Moxley RT III, Heine R, Lehmann-Horn F. Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol 1994;51:1095-1102.
80. Rudel R, Ricker K, Lehmann-Horn F. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol 1993;50:1241-1248.
81. Colding-Jorgensen E, Duno M, Vissing J. Autosomal dominant monosymptomatic myotonia permanens. Neurology 2006;67:153-155.
82. Lehmann-Horn F, Rudel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol 1995;8:402-410.
83. Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology 1987;37:488-491.
84. Ptacek LJ, Tawil R, Griggs RC, Storvick D, Leppert M. Linkage of atypical myotonia congenita to a sodium channel locus. Neurology 1992;42:431-433.
85. Miller TM, Dias da Silva MR, Miller HA, Kwiecinski H, Mendell JR, Tawil R, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology 2004;63:1647-1655.
86. Sansone V, Links T, Meola G, Rose MR. Treatment for periodic paralysis. Cochrane Database Syst Rev 2006;2.
87. Sansone V, Meola G, Links TP, Panzeri M, Rose MR. Treatment for periodic paralysis. Cochrane Database Syst Rev 2008;(1):CD005045.
88. McManis PG, Lambert EH, Daube JR. The exercise test in periodic paralysis. Muscle Nerve 1986;9:704-710.
89. Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M, Labarre-Vila A, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve 2000;23:1089-1094.
90. Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, et al. Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies. Ann Neurol 2011;69:328-340.
91. Gadalla SM, Lund M, Pfeiffer RM, Gortz S, Mueller CM, Moxley RT III, et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011;306:2480-2486.
92. Heatwole CR, Miller J, Martens B, Moxley RT III. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol 2006;63:1149-1153.
93. Heatwole C, Johnson N, Goldberg B, Martens W, Moxley R III. Laboratory abnormalities in patients with myotonic dystrophy type 2. Arch Neurol 2011;68:1180-1184.
94. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 2003;60:1854-1857.
95. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004;29:275-281.
96. Pisani V, Panico MB, Terracciano C, Bonifazi E, Meola G, Novelli G, et al. Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 2008;38:1405-1411.
97. Liquori CL, Ikeda Y, Weatherspoon M, Ricker K, Schoser BG, Dalton JC, et al. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003;73:849-862.
98. Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics 2007;4:216-224.
99. McClatchey AI, McKenna-Yasek D, Cros D, Worthen HG, Kuncl RW, DeSilva SM, et al. Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. Nat Genet 1992;2:148-152.
100. Wagner S, Lerche H, Mitrovic N, Heine R, George AL, Lehmann-Horn F. A novel sodium channel mutation causing a hyperkalemic paralytic and paramyotonic syndrome with variable clinical expressivity. Neurology 1997;49:1018-1025.
101. Fialho D, Schorge S, Pucovska U, Davies NP, Labrum R, Haworth A, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain 2007;130:3265-3274.
102. Meyer-Kleine C, Ricker K, Otto M, Koch MC. A recurrent 14 bp deletion in the CLCN1 gene associated with generalized myotonia (Becker). Hum Mol Genet 1994;3:1015-1016.
103. Nagamitsu S, Matsuura T, Khajavi M, Armstrong R, Gooch C, Harati Y, et al. A "dystrophic" variant of autosomal recessive myotonia congenita caused by novel mutations in the CLCN1 gene. Neurology 2000;55:1697-1703.
104. Matthews E, Tan SV, Fialho D, Sweeney MG, Sud R, Haworth A, et al. What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. Neurology 2008;70:50-53.
105. Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86:371-375.
106. Pouget J, Serratrice G. Myotonia with muscular weakness corrected by exercise. The therapeutic effect of mexiletine. Rev Neurol (Paris) 1983;139:665-672.
107. Leheup B, Himon F, Morali A, Brichet F, Vidailhet M. Value of mexiletine in the treatment of Thomsen-Becker myotonia. Arch Fr Pediatr 1986;43:49-50.
108. Logigian EL, Martens WB, Moxley RT IV, McDermott MP, Dilek N, Wiegner AW, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;74:1441-1448.
109. Lion-Francois L, Mignot C, Vicart S, Manel V, Sternberg D, Landrieu P, et al. Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. Neurology 2010;75:641-645.
110. Barohn R, Wang Y, Herbelin L, Bundy B, Trivedi J, Hanna M, et al. Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia. Neurology 2011;76(suppl 4):S56.004:A645.
111. Jurkat-Rott K, Lehmann-Horn F. Human muscle voltage-gated ion channels and hereditary disease. Curr Opin Pharmacol 2001;1:280-287.
112. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999;79:1317-1372.
113. Desaphy JF, De Luca A, Tortorella P, De Vito D, George AL Jr, Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 2001;57:1849-1857.
114. Campbell RW. Mexiletine. N Engl J Med 1987;316:29-34.
115. Streib EW. Paramyotonia congenita: successful treatment with tocainide. Clinical and electrophysiologic findings in seven patients. Muscle Nerve 1987;10:155-162.
116. Streib EW. Successful treatment with tocainide of recessive generalized congenital myotonia. Ann Neurol 1986;19:501-504.
117. Mielke U, Haass A, Sen S, Schmidt W. Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. J Neurol 1985;232:271-274.
118. Feinberg L, Travis WD, Ferrans V, Sato N, Bernton HF. Pulmonary fibrosis associated with tocainide: report of a case with literature review. Am Rev Respir Dis 1990;141:505-508.
119. Roden DM, Woosley RL. Drug therapy. Tocainide. N Engl J Med 1986;315:41-45.
120. Catalano A, Carocci A, Corbo F, Franchini C, Muraglia M, Scilimati A, et al. Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents. Eur J Med Chem 2008;43:2535-2540.
121. Aoike F, Takahashi MP, Sakoda S. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation. Eur J Pharmacol 2006;532:24-31.
122. Rosenfeld J, Sloan-Brown K, George AL Jr. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 1997;42:811-814.
123. Wang DW, VanDeCarr D, Ruben PC, George AL Jr, Bennett PB. Functional consequences of a domain 1/S6 segment sodium channel mutation associated with painful congenital myotonia. FEBS Lett 1999;448:231-234.
124. Finlay M. A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1982;45:461-463.
125. Munsat TL. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology 1967;17:359-367.
126. Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain 1959;82:81-91.
127. Fitting JW, Leuenberger P. Procainamide for dyspnea in myotonic dystrophy. Am Rev Respir Dis 1989;140:1442-1445.
128. Finkel MJ. Phenytoin revisited. Clin Ther 1984;6:577-591.
129. Sugino M, Ohsawa N, Ito T, Ishida S, Yamasaki H, Kimura F, et al. A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy. Neurology 1998;51:586-589.
130. Bissay V, Keymolen K, Lissens W, Laureys G, Schmedding E, Keyser JD. Late onset painful cold-aggravated myotonia: three families with SCN4A L1436P mutation. Neuromuscul Disord 2011;21:590-593.
131. Lyons MJ, Duron R, Molinero I, Sangiuolo F, Holden KR. Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita. Pediatr Neurol 2010;42:365-368.
132. Berardinelli A, Gorni K, Orcesi S. Response to carbamazepine of recessive-type myotonia congenita. Muscle Nerve 2000;23:138-39.
133. Savitha MR, Krishnamurthy B, Hyderi A, Farhan-Ul-Haque, Ramachandra NB. Myotonia congenita-a successful response to carbamazepine. Indian J Pediatr 2006;73:431-433.
134. Sechi GP, Traccis S, Durelli L, Monaco F, Mutani R. Carbamazepine versus diphenylhydantoin in the treatment of myotonia. Eur Neurol 1983;22:113-118.
135. Durelli L, Mutani R, Fassio F. The treatment of myotonia: evaluation of chronic oral taurine therapy. Neurology 1983;33:599-603.
136. Diacono J, Dietrich J. Effects of taurine on the transmembrane ionic currents of rat and guinea pig ventricular fibres. Farmaco Sci 1976;31:277-283.
137. Kendler BS. Taurine: an overview of its role in preventive medicine. Prev Med 1989;18:79-100.
138. Shao A, Hathcock JN. Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol 2008;50:376-399.
139. Gascon GG, Staton RD, Patterson BD, Konewko PJ, Wilson H, Carlson KM, et al. A pilot controlled study of the use of imipramine to reduce myotonia. Am J Phys Med Rehabil 1989;68:215-220.
140. Keltner L, Folks D, Keltner L, Folks D. In: Psychotropic drugs. St. Louis, MO: Elsevier Mosby; 2005. p 643.
141. D'Agostino ML, Risser J, Robinson-Bostom L. Imipramine-induced hyperpigmentation: a case report and review of the literature. J Cutan Pathol 2009;36:799-803.
142. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007;151:737-748.
143. Antonini G, Vichi R, Leardi MG, Pennisi E, Monza GC, Millefiorini M. Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial. Neurology 1990;40:1473-1474.
144. Milner-Brown HS, Miller RG. Myotonic dystrophy: quantification of muscle weakness and myotonia and the effect of amitriptyline and exercise. Arch Phys Med Rehabil 1990;71:983-987.
145. Grant R, Sutton DL, Behan PO, Ballantyne JP. Nifedipine in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1987;50:199-206.
146. Cleland JC, Griggs RC. Treatment of neuromuscular channelopathies: current concepts and future prospects. Neurotherapeutics 2008;5:607-612.
147. Eguchi H, Tsujino A, Kaibara M, Hayashi H, Shirabe S, Taniyama K, et al. Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve 2006;34:292-297.
148. Griggs RC, Moxley RT III, Riggs JE, Engel WK. Effects of acetazolamide on myotonia. Ann Neurol 1978;3:531-537.
149. Riggs JE, Griggs RC, Moxley RT. Acetazolamide-induced weakness in paramyotonia congenita. Ann Intern Med 1977;86:169-173.
150. Torres C, Moxley RT, Griggs RC. Quantitative testing of handgrip strength, myotonia, and fatigue in myotonic dystrophy. J Neurol Sci 1983;60:157-168.
151. Kwiecinski H. Treatment of myotonic dystrophy with acetazolamide. J Neurol 1980;222:261-263.
152. Tawil R, Moxley RT III, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993;43:1105-1106.
153. Pusponegoro HD, Zacharia J, Passat J. Myotonia congenita (Thomsen's disease) report of five cases in a family. Paediatr Indones 1991;31:170-178.
154. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm167883.htm(accessed 8/23/12).
155. Ohtaki E, Komori H, Yamaguchi Y, Matsuishi T. Successful dantrolene sodium treatment of a patient with myotonia congenita (Thomsen's disease). Acta Paediatr Jpn 1991;33:668-671.
156. Phillips DC, Ellis FR, Exley KA, Ness MA. Dantrolene sodium and dystrophia myotonica. Anaesthesia 1984;39:568-573.